Bladder cancer
Conditions
Interventions
None listed
Sponsors
The University of Texas MD Anderson Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Non-muscle-invasive bladder (Ta, Tis, and T1) patients who were newly diagnosed (within 1 year before recruitment) between 1997 and 2012, with histologic confirmation, and were previously untreated with chemotherapy or radiotherapy. For the present study, we limited the analysis to non-Hispanic whites who account for the majority of the study population.
Exclusion criteria
Exclusion criteria: Patients with outlying (i.e., outside the interval delimited by the 25th percentile minus 1.5 times the interquartile range and the 75th percentile plus 1.5 times the interquartile range) or implausible (i.e., <500 kcal/d or >5,000 kcal/d) energy intakes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor recurrence was defined as a newly found bladder tumor during follow-up, and progression was defined as the transition from non-muscle-invasive to invasive or metastatic disease during follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Stratified associations by treatments. Folate intake and five tumor characteristics at diagnosis: focality, size, grade, stage, and concomitant carcinoma in situ. | — |
Countries
North America
Contacts
Public ContactDr. Huakang Tu
The University of Texas MD Anderson Cancer Center Division of Cancer Prevention & Population Sciences
Outcome results
None listed